- Investor's Business Daily•43 minutes ago
Biogen could add another $1 billion in 2017 sales if its myotonic dystrophy drug garners strong trials data by year's end, says an analyst.
- American City Business Journals•54 minutes ago
Earnings season for our Massachusetts biotech giants kicks off this week when Vertex Pharmaceuticals reports its third quarter financials on Tuesday evening, followed by Biogen on Wednesday morning. While probably just a fluke, it’s unusual for Vertex (VRTX) to be the first local biotech to give a quarterly update, as that honor usually goes to Biogen (BIIB). Vertex : To some extent, the financial news expected from the Boston-based company is already old news.
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||290.78 x 900|
|Ask||293.20 x 500|
|Day's Range||290.00 - 293.40|
|52wk Range||223.02 - 333.65|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||16.99|
|Avg Vol (3m)||1,568,714|
|Dividend & Yield||N/A (N/A)|